Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Recruiting 6Terminated 5Active not recruiting 5Withdrawn 2Not yet recruiting 2Completed 1

Sponsor Class

INDUSTRY 4NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5Gastrointestinal 3CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Neoplasm Metastasis 3Lung Neoplasms 3Neoplasms 1

Interventions

Carboplatin 134pembrolizumab 113Pemetrexed 94Cisplatin 88durvalumab 62Paclitaxel 60osimertinib 54Nivolumab 54Docetaxel 44atezolizumab 41Etoposide 30Radiotherapy 28Radiosurgery 26Gemcitabine 26Specimen Handling 24Ipilimumab 23Taxes 19Magnetic Resonance Spectroscopy 19amivantamab 16130-nm albumin-bound paclitaxel 16Drug Therapy 15Bevacizumab 15Radiation 14Platinum 14Immunoglobulin G 14Disulfides 14cemiplimab 13Crizotinib 13Cyclophosphamide 12Biopsy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × adagrasib × Thoracic × Clear all
NCT05673187 2026-04-27

ADEPPT

ETOP IBCSG Partners Foundation

Phase 2 Active not recruiting
68 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06497556 2026-04-20

Krascendo 1

Hoffmann-La Roche

Phase 3 Active not recruiting
338 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05853575 2026-03-27

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

Mirati Therapeutics Inc.

Phase 2 Active not recruiting
200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT05375994 2025-05-18

RAMP204

Verastem, Inc.

Phase 1/2 Active not recruiting
85 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

NCT04685135 2025-01-22

KRYSTAL-12

Mirati Therapeutics Inc.

Phase 3 Active not recruiting
453 enrolled 20 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡